|
|
Post by dayanand33 on Jan 26, 2015 13:49:05 GMT
Thread to discuss BTX in general
|
|
|
|
Post by dayanand33 on Jan 26, 2015 13:50:21 GMT
|
|
|
|
Post by dayanand33 on Jan 26, 2015 13:51:38 GMT
I like this stock but still keep away from it because of lack of any near term catalysts. I am wary that the short sellers might consider this as a sitting duck.
|
|
|
|
Post by mycargoesfast on Jan 26, 2015 14:05:05 GMT
The timing is suspicious, It bounced off 52 week highs about 2 weeks ago and has been dropping daily ever since (luckily I sold at the high point). Was the run up due to Broadwood capitol buying up shares? I Doubt it since they declared their intent to buy back in October 2014. I'm also not buying the whole it's a great investment because of the board, I'm not sure what Questcor's product was but I'm assuming it was a great product that sold that realized such gains not actions from the board.
I do like BTX stock, it has returned good gains for me, I just think it's got some room to drop some more after the Seeking Alpha bump clears out.
|
|
|
|
Post by mycargoesfast on Jan 26, 2015 14:29:56 GMT
|
|
|
|
Post by dayanand33 on Jan 26, 2015 14:41:20 GMT
With over 600 patents this can prove to a very good "patent war" play. Once these stem cell cos cross Phase III and start commercialization , it could get very ugly with patent lawsuits. But that is still a long way to go. |
|
|
|
Post by JHam on Mar 19, 2015 18:55:54 GMT
With over 600 patents this can prove to a very good "patent war" play. Once these stem cell cos cross Phase III and start commercialization , it could get very ugly with patent lawsuits. But that is still a long way to go. Not sure what is going on with this one today, but something is up. Went as high as $5.40 a bit ago on very high volume. |
|
|
|
Post by JHam on Mar 20, 2015 13:08:18 GMT
|
|
|
|
Post by mycargoesfast on Mar 21, 2015 2:01:44 GMT
I sold my position in BTX about a month ago, kicking myself since. Seems BTX has more iron's in the fire than I gave them credit for: seekingalpha.com/news/2380346-investors-appear-to-wake-up-to-potential-of-biotimes-asthma-iphone-app Thinly-traded small cap BioTime (BTX +16.1%) jumps on a 4x surge in volume in (what appears to be) belated response to the March 9 announcement by Mount Sinai's Icahn School of Medicine that it is launching a large-scale research study of asthma using Apple's ResearchKit iPhone software. The Asthma Health app was developed by Mount Sinai in conjunction with LifeMap Solutions, a subsidiary of BioTime's LifeMap Sciences. LifeMap Solutions is working with the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai to develop big data analytics algorithms to process the enormous volume of study data. Researchers hope that it will lead to new discoveries about asthma and improved chronic disease management. |
|
|
|
Post by JHam on Mar 24, 2015 15:05:05 GMT
Another big day so far for BTX on big volume. So much for this one going under a dollar anytime soon as was predicted not too long ago, lol.
|
|
|
|
Post by selluwud on Dec 22, 2015 13:59:14 GMT
Good volume yesterday and active in pre-market today, what's up???
|
|
|
|
Post by JHam on Dec 22, 2015 14:17:11 GMT
Good volume yesterday and active in pre-market today, what's up??? Not sure. They still have not signed on with a new partner after Teva dropped them. West said they were going to be looking for someone else so who knows. Maybe something to do with OCAT? |
|
|
|
Post by selluwud on Dec 22, 2015 14:50:23 GMT
Upgraded by Oppenheimer ?
|
|
|
|
Post by imz72 on Dec 23, 2015 4:46:01 GMT
Upgraded by Oppenheimer ?
December 22nd, 2015 BioTime logoEquities researchers at Oppenheimer assumed coverage on shares of BioTime, Inc. (NYSEMKT:BTX) in a report released on Tuesday, The Fly reports. The brokerage set an “outperform” rating and a $10.00 price target on the biotechnology company’s stock. Oppenheimer’s target price indicates a potential upside of 151.26% from the stock’s previous close. Shares of BioTime (NYSEMKT:BTX) traded down 0.24% during midday trading on Tuesday, hitting $4.14. 220,040 shares of the company were exchanged. The stock’s 50-day moving average is $3.58 and its 200-day moving average is $3.49. BioTime has a one year low of $2.20 and a one year high of $5.95. The stock’s market cap is $339.66 million. In other news, insider Alfred D. Kingsley sold 100,000 shares of the firm’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $3.83, for a total transaction of $383,000.00. Following the completion of the transaction, the insider now directly owns 5,938,055 shares of the company’s stock, valued at approximately $22,742,750.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen C. Farrell acquired 50,000 shares of BioTime stock in a transaction dated Friday, November 6th. The shares were acquired at an average cost of $3.83 per share, with a total value of $191,500.00. Following the completion of the acquisition, the director now directly owns 97,450 shares in the company, valued at approximately $373,233.50. www.americanbankingnews.com/2015/12/22/oppenheimer-initiates-coverage-on-biotime-inc-btx/ |
|
|
|
Post by dayanand33 on Jan 4, 2016 17:29:55 GMT
What's up with this stock? Went over 30% over 2 weeks and opened 8%up only to go down 15%.
It subsidiary OncoCyte is up 45% on its first day. Height of irrationality.
|
|
